+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton-pump inhibitor use and the risk for community-acquired pneumonia



Proton-pump inhibitor use and the risk for community-acquired pneumonia



Annals of Internal Medicine 149(6): 391-398



Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP). To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom. Nested case-control study. The General Practice Research Database (1987 to 2002) in the United Kingdom. Patients age 18 years or older with at least 6 months of initial pneumonia-free follow-up in the database. Case patients (n = 80 066) were defined as those who received an incident diagnosis of CAP. Control participants (n = 799 881) were selected by using incidence density sampling, matching on practice site, calendar period, and follow-up duration. Use of PPIs within 30 days before the index date. Adjusted odds ratios (ORs) were estimated by using conditional logistic regression, adjusting for potential confounders. Overall, current PPI use was not associated with an increased risk for CAP (adjusted OR, 1.02 [95% CI, 0.97 to 1.08]) or risk for CAP that required hospitalization (adjusted OR, 1.01 [CI, 0.91 to 1.12]). There was a strong increase in risk for CAP associated with current use of PPI therapy that was started within the previous 2 days (adjusted OR, 6.53 [CI, 3.95 to 10.80]), 7 days (adjusted OR, 3.79 [CI, 2.66 to 5.42]), and 14 days (adjusted OR, 3.21 [CI, 2.46 to 4.18]), but there was no statistically significant association for longer-term current PPI therapy. A separate matched case-control analysis, which included the 3 strongest confounders as additional matching factors, yielded similar results as the primary analysis (adjusted OR, 0.96 [CI, 0.91 to 1.02]). Adherence to PPI prescription was assumed to be 100%. No radiographic evidence was available to corroborate a diagnosis of CAP. Proton-pump inhibitor therapy started within the past 30 days was associated with an increased risk for CAP, whereas longer-term current use was not.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260842

Download citation: RISBibTeXText

PMID: 18794558

DOI: 10.7326/0003-4819-149-6-200809160-00005


Related references

Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Alimentary Pharmacology & Therapeutics 31(11): 1165-1177, 2011

Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. Journal of General Internal Medicine 28(2): 223-230, 2013

Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. Plos One 10(6): E0128004-E0128004, 2016

Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Alimentary Pharmacology & Therapeutics 36(10): 941-949, 2013

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Bmj 355: I5813-I5813, 2017

Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clinical Infectious Diseases 54(1): 33-42, 2012

Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. Journal of the American Geriatrics Society: -, 2018

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Archives of Internal Medicine 167(9): 950-955, 2007

Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 63(4): 552-558, 2014

The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis. Annals of PharmacoTherapy: 1060028018760569-1060028018760569, 2018

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Cmaj 175(7): 745-748, 2006

Community-acquired pneumonia and proton pump inhibitors. Journal of General Internal Medicine 28(7): 872-872, 2014

Community-acquired pneumonia and proton pump inhibitors. Journal of General Internal Medicine 28(7): 873-873, 2014

Proton pump inhibitors and community acquired pneumonia. Bmj 355: I6041-I6041, 2016

Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Review of Clinical Pharmacology 5(3): 337-344, 2012